Structure of the Herpes Simplex Virus Receptor
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Nov 3, 1999
Trial Information
Current as of March 27, 2025
Completed
Keywords
ClinConnect Summary
Herpes simplex virus (HSV) causes genital, orolabial, or cutaneous lesions, keratitis, and encephalitis. Recently cellular receptors for HSV were isolated. The purpose of this study is to identify polymorphisms in the sequence of HSV receptor, cytokines or chemokines and to determine whether these polymorphisms correlate with susceptibility to infection by HSV or with symptoms of HSV. Blood samples from individuals who are seronegative, or seropositive (with or without symptoms of infection) for HSV-2 will be analyzed to determine the sequences of the HSV receptors, cytokines, chemokines, o...
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- HSV-2 Seronegative Patients:
- • Individuals known or likely to be seronegative for HSV-2 will be recruited.
- • All racial, gender, and ethnic groups will be considered.
- • Adult volunteers at least 18 years of age.
- • Volunteers who were seronegative for HSV-2 (regardless of HSV-1 serology) confirmed by Western blot.
- • Volunteers are willing to allow investigators to store their blood.
- HSV-2 seropositive patients (with or without symptoms):
- • All racial and ethnic groups will be considered.
- • Volunteers who were seropositive for HSV-2 (regardless of HSV-1 serology) confirmed by Western blot.
- • Volunteers are willing to allow investigators to store their blood.
- Normal Controls:
- • To determine the frequency of a genetic polymorphism in a population that has not had prior screening for HSV, blood may be obtained from normal control blood donors.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials